



Government of the Republic of Trinidad and Tobago
Ministry of Health

OFFICE OF THE CHIEF MEDICAL OFFICER
#63 Park Street, Port of Spain 100607

MEMORANDUM

From: Chief Medical Officer
To: President, Medical Board of Trinidad and Tobago
Date: 10th August, 2021
Subject: **World Health Organization advice on the use of Ivermectin to Treat COVID-19 Patients**

The subject matter at caption refers

The World Health Organization (WHO), recognized the urgent need for global collaboration to provide trustworthy and evolving COVID-19 guidance and informing on policy and practices worldwide.

The recommendations from the international Guideline Development Group (GDG) of content experts, clinicians, patients, ethicists and methodologists regarding COVID-19 treatment, has not recommended Ivermectin for COVID-19 treatment and prevention. The following Population Intervention Comparator Outcome (PICO) refers:

Table 1: Clinical Questions / PICO

OUTCOME (time frame)	SUMMARY
Mortality	The effect of Ivermectin on mortality is uncertain.
Mechanical Ventilation	The effect of Ivermectin on mechanical ventilation is uncertain
Viral Clearance (7days)	Ivermectin may increase or have no effect on viral clearance.
Hospital Admission (outpatient only)	The effect of Ivermectin on hospital admission is uncertain.
Severe Adverse Events	Ivermectin may increase the risk of serious adverse events leading to drug discontinuation.
Time to clinical improvement	Ivermectin may have little or no difference on time to clinical improvement



1(868) 627-0010/12/14
Ext. 1616, 1617



1(868) 623-3755



www.health.gov.tt



cmo@health.gov.tt

